Mon-Fri, 8:30 am-7 pm ET P: 1-844-864-8437 F: 1-800-380-5294



TYVASO® (treprostinil) & TYVASO DPI® (treprostinil) Enrollment and Referral Form

Follow the steps to prescribe TYVASO or TYVASO DPI for your patient and get them started with support from United Therapeutics Cares.

Accredo Health Group, Inc. OCVS Specialty Pharmacy

	\bigcirc	Complete all	required	sections
--	------------	--------------	----------	----------

- Provide copies of insurance cards (front and back)
- Gather patient signatures
- Fax referral and documentation

*Required

							•
Who is the patient?							
*First name, middle initial			*Last name				
*Date of birth (MM/DD/YYYY)	*Gender: Male) Female	*Email				
*Home address				*City		*State	*ZIP
Shipping address (if different from home)				City		State	ZIP
*Phone		Pers	onal \(\) Work	Best time to call: OMo	orning O	Afternoon C) Evening
OK to leave a message? Yes No	Primary language						
Caregiver/Family member name			Caregiver ema	il			
Caregiver phone		Pers	onal \(\) Work	Best time to call: OMo	orning O	Afternoon C) Evening
The patient authorizes the caregiver to recei	ve information regarding the	e patient's	s treatment and	care: OYes ONo			
*Patient therapy status for TYVASO : New	w ○ Restart ○ Transition	n *Patie	ent therapy statu	s for TYVASO DPI:	New ORe	start OTra	nsition
Who is the prescriber?							
Wilo is the presenter.							
*First name			*Last name				
*Office/Clinic/Institution			*State license	#	*NF	기	
*Office address				*City		*State	*ZIP
*Office contact			*Phone				
Office contact email			*Fax				
What is the patient's insur	ance?						
Primary prescription insurance							
Subscriber ID #			Group #		Phone		
Primary medical insurance					Policy hol	der	
Subscriber ID #			Group #		Phone		
Who is the preferred Speci	alty Pharmacy?						
who is the preferred speci	arcy i marmacy:						



Sign here:

DAW:

Questions about filling out this form? Reach out to the United Therapeutics Cares™ Team.

Mon-Fri, 8:30 am-7 pm ET P: 1-844-864-8437 F: 1-800-380-5294



Fill out this page for PH-ILD patients *Date of birth (MM/pp/yyyy) *Patient name: PH-ILD: What is the patient's clinical history? ○kg ○lb WHO group NYHA functional class: OI OII OIII OIV *Weight *Known drug allergies None Yes, please list: *PH Diagnosis Codes (choose one): ICD-10 I27.23: OPulmonary hypertension due to lung diseases and hypoxia Other ICD-10: *ILD Diagnosis Codes (choose one): IIP: ICD-10 J84.10: O Pulmonary fibrosis, unspecified ICD-10 J84.111: O Idiopathic interstitial pneumonia, NOS ICD-10 J84.112: O Idiopathic pulmonary fibrosis CTD-related ILD: ICD-10 M34.81: Systemic sclerosis with lung involvement Environmental/Occupational Lung Disease: ICD-10 J61: Pneumoconiosis due to asbestos and other mineral fibers ICD-10 J67.9: Hypersensitivity pneumonitis due to unspecified dust Other causes: ICD-10 J17: OPneumonia in disease classified elsewhere Other ICD-10: PH-ILD: What is the patient's TYVASO or TYVASO DPI prescription? TYVASO (treprostinil) 1.74mg/2.9ml ampule (0.6mg/ml) Inhalation Solution Dose comparison Target dose: 9 breaths (54 mcg) to 12 breaths (72 mcg), QID TYVASO DPI **TYVASO Nebulizer Cartridge Strength** # of Breaths mcg per treatment session, QID Start with 3 breaths (18 mcg) QID (if 3 breaths are not tolerated, use 1 to 2 breaths). Increase by an additional 16 mcg <5 1-3 breaths every week, as tolerated, until the maintenance dose is achieved. 6 to 7 32 mca TYVASO Inhalation System Starter Kit (28-day supply) 0 refills TYVASO Inhalation System Refill Kit (28-day supply) X 8 to 10 refills 48 mcg 11 to 13 64 mca -OR- TYVASO DPI (treprostinil) Inhalation Powder 80 mcg 14 to 15 **Target dose**: ○ 48 mcg ○ 64 mcg ○ 80 mcg ○ 96 mcg ○ 112 mcg ○ 128 mcg 96 mcg ~18* Other mcg per treatment session, QID Start by taking one breath, per cartridge, (16mcg), QID. Increase cartridge strength by 16 mcg every 1-2 weeks 112 mcg ~21* as tolerated to reach maintenance dose. Titration schedule may vary based on tolerability. If the prescribed dose 128 mcg ~24* is higher than 64 mcg per treatment session, more than 1 cartridge will be needed per session. **TYVASO DPI Titration Kit (28-day supply)** TYVASO DPI Maintenance Kit (28-day supply) *Based on extrapolation of lower doses assuming linearity Choose for titration phase. refills Specify any additional dosing, titration, and/or 16 mcg (112 ct), 32 mcg (112 ct), and Check all that apply to achieve maintenance dose. side effect management instructions: ○ 16 mcg (112 ct) ○ 32 mcg (112 ct) 48 mcg (28 ct) 1 refill ○ 48 mcg (112 ct) ○ 64 mcg (112 ct) Nursing Visit Orders (select one): RN to provide assessment and education on administration, dosing, titration, and side effect management. OSpecialty Pharmacy Home Healthcare RN visit Prescriber-directed Specialty Pharmacy RN visit as detailed: Location (select one): Home Outpatient Clinic Hospital Prescriber signature: Prescription and statement of medical necessity I certify that the medication ordered above is medically necessary and that I am personally supervising the care of this patient. I authorize United Therapeutics Cares to act on my behalf for the limited purposes of transmitting this prescription to the appropriate pharmacy designated by the patient utilizing their benefit plan. PRESCRIBER SIGNATURE REQUIRED TO VALIDATE PRESCRIPTIONS. Prescriber attests this is his/her legal signature. No stamps. Prescriptions must be faxed. Physician's signature Physician's signature Date (dispense as written) (substitution allowed) State-Specific Dispense as Written (DAW) Selection Verbiage:



Sign here:

DAW:

Questions about filling out this form? Reach out to the United Therapeutics Cares™ Team.

Mon-Fri, 8:30 am-7 pm ET P: 1-844-864-8437 F: 1-800-380-5294



Fill out this page for PAH patients *Patient name: *Date of birth (MM/pp/yyyy) PAH: What is the patient's clinical history? \bigcirc kg \bigcirc lb WHO group *Weight *NYHA functional class: OI OII OIII OIV *Known drug allergies None Yes, please list: *List PAH-specific medications patient is on or has taken: *ICD-10 I27.0 Primary pulmonary hypertension: Oldiopathic PAH OHeritable PAH Other ICD-10: *ICD-10 I27.21 Secondary pulmonary hypertension: Oconnective tissue disease Ocongenital heart disease Drugs/Toxins induced HIV Other: Please indicate if the patient named was trialed on a Calcium Channel Blocker prior to the initiation of therapy. No, reason for not using: Yes, with the following results: PAH: What is the patient's TYVASO or TYVASO DPI prescription? TYVASO (treprostinil) 1.74mg/2.9ml ampule (0.6mg/ml) Inhalation Solution Dose comparison Target dose: 9 breaths (54 mcg) to 12 breaths (72 mcg), QID TYVASO DPI TYVASO Nebulizer # of Breaths Cartridge Strength mcg per treatment session, QID Start with 3 breaths (18 mcg) QID (if 3 breaths are not tolerated, use 1 to 2 breaths). Increase by an additional 16 mcg 1-3 breaths every week, as tolerated, until the maintenance dose is achieved. 32 mcg 6 to 7 TYVASO Inhalation System Starter Kit (28-day supply) 0 refills TYVASO Inhalation System Refill Kit (28-day supply) X 48 mcg 8 to 10 64 mcg 11 to 13 -OR- TYVASO DPI (treprostinil) Inhalation Powder 80 mca 14 to 15 **Target dose**: () 48 mcg () 64 mcg () 80 mcg () 96 mcg () 112 mcg () 128 mcg 96 mca ~18* mcg per treatment session, QID Start by taking one breath, per cartridge, (16mcg), QID. Increase cartridge strength by 16 mcg every 1-2 weeks 112 mcg ~21* as tolerated to reach maintenance dose. Titration schedule may vary based on tolerability. If the prescribed dose 128 mcg ~24* is higher than 64 mcg per treatment session, more than 1 cartridge will be needed per session. TYVASO DPI Maintenance Kit (28-day supply) **TYVASO DPI Titration Kit (28-day supply)** *Based on extrapolation of lower doses assuming linearity Choose for titration phase. refills Specify any additional dosing, titration, and/or 16 mcg (112 ct), 32 mcg (112 ct), and Check all that apply to achieve maintenance dose. side effect management instructions: ○ 16 mcg (112 ct) ○ 32 mcg (112 ct) 48 mcg (28 ct) 1 refill ○ 48 mcg (112 ct) ○ 64 mcg (112 ct) Nursing visit orders (select one): RN to provide assessment and education on administration, dosing, titration, and side effect management. Ospecialty Pharmacy Home Healthcare RN visit Prescriber-directed Specialty Pharmacy RN visit as detailed: Location (select one): Home Outpatient Clinic Hospital Prescriber signature: Prescription and statement of medical necessity I certify that the medication ordered above is medically necessary and that I am personally supervising the care of this patient. I authorize United Therapeutics Cares to act on my behalf for the limited purposes of transmitting this prescription to the appropriate pharmacy designated by the patient utilizing their benefit plan. PRESCRIBER SIGNATURE REQUIRED TO VALIDATE PRESCRIPTIONS. Prescriber attests this is his/her legal signature. No stamps. Prescriptions must be faxed. Physician's signature Physician's signature Date (dispense as written) (substitution allowed) State-Specific Dispense as Written (DAW) Selection Verbiage:

Please note: The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is the responsibility of the provider. The information provided here, or through United Therapeutics Cares, is not a guarantee of coverage or reimbursement.



Check here:

Check here:

Check here:

Sign here:

signature

Questions about filling out this form? Reach out to the United Therapeutics Cares™ Team.

Mon-Fri, 8:30 am-7 pm ET P: 1-844-864-8437 **F:** 1-800-380-5294



	*Patient name:			*Date of birth	1 (MM/DD/YYYY)	
	Please have the	e patient complete and sign				
	Consent to enrollment in United Therapeutics Cares					
		Enrollment in United Therapeutics Cares By submitting this form, I am enrolling in United Therapeutics Cares and authorize United Therapeutics Corporation, ts affiliates, vendors, agents, and representatives (collectively, "United Therapeutics") to provide me services (the "Services"). These Services include:				
	1 Access and Affordability Support: United Therapeutics Cares provides support to educate patients and caregivers on their insurance coverage, answer access-related questions, and discuss financial assistance eligibility and enrollment options. 3 Coordination: United Therapeutics Cares offers a dedicated point contact who works with patients and their caregivers, Specialty Pharmacies, and healthcare providers to help reduce nonclinical to therapy, including conducting prescription triage, coordinating			caregivers, Specialty nelp reduce nonclinical barriers ion triage, coordinating delivery,		
	•	United Therapeutics Cares offers a dedicated point of disease and product education support to patients	4 Patient Assista	ance Program: United The gram for uninsured and un	ng basis post therapy initiation. erapeutics Cares offers a free derinsured patients who meet	
		ervices does not guarantee that any service(s) will be provibility for and provide the services. Consent is not required		•	9	
		y If enrolling in the Patient Assistance Program, I authori vider and reviewing additional insurance, medical, or fina				
	information solely to d	By checking this box, I authorize United Therapeutics and its vendors, under the Fair Credit Reporting Act, to obtain my credit profile or other relevant information solely to determine eligibility for the Patient Assistance Program. Upon request, United Therapeutics will inform me whether a consumer report was requested and provide the agency's contact details. Enrollment and continuation are subject to timely income verification.				
	Conditions of Participation If I receive free medication through the Patient Assistance Program, I will not seek reimbursement from government-funded healthcare programs (Medicare/Medicaid/Veterans Administration/Department of Defense) or submit related costs to any health plan, foundation, Flexible Spending Account (FSA), or Health Savings Account (HSA). I will notify United Therapeutics Cares of any changes in my insurance or financial status and certify that all provided information is complete and accurate. United Therapeutics Cares may be modified or discontinued without notice.					
	Use of Personal Information By submitting this form, I consent to the collection, use, and disclosure of my personal health and contact information for service provision and other business purposes, as outlined in the United Therapeutics Privacy Statement (unither.com/privacy). Depending on my location, I may have rights regarding my personal information, including requests for access or deletion. California residents should refer to the CCPA Notice within the Privacy Statement. Requests to exercise these rights can be made at 844-864-8437 or privacyoffice@unither.com.					
	Communications Consent					
	By checking the box(es) below, I hereby provide my consent to receive certain communications from United Therapeutics and its agents (including service providers on its behalf) by mail, fax, email, telephone (including cell phone), and text message. I understand and acknowledge that my personal information, including health information, may be used or disclosed as part of the communications. Communications transmitted via unencrypted email or text message over an open network may be inherently unsecure, and there is no assurance of confidentiality for information communicated in this manner.					
	Text Communications Authorization					
•	OI consent to receive automated text messages from United Therapeutics Cares at my provided mobile number. Message and data rates may apply. Frequency varies. I understand consent is not required for participation in United Therapeutics Cares or to purchase goods or services. I can reply HELP for help and STOP to opt out anytime. Information processing is subject to the United Therapeutics Privacy Statement, unither.com/privacy, and Text Message Terms and Conditions, unither.com/textterms.					
	Product Information Communications					
	If available for my United Therapeutics medication, I consent to enrollment into and access to a secure portal with personalized resources, including tips, best practices, and education to support my therapy and any associated devices. I also consent to receive communications by mail, email, and telephone (including cell phone), including through automated technologies, at the number and address I have provided from United Therapeutics regarding its products, programs, services, disease state materials, educational and adherence materials, promotions, research and surveys, and other research opportunities. I understand I can update preferences and/or opt out at any time. I also know the processing of my information is subject to the United Therapeutics Privacy Statement, unither.com/privacy.					
	Additional Information If you have questions, want to update your information, or terminate your enrollment, please call 844-864-8437 Monday–Friday, 8:30 am–7 pm ET, or write to us at P.O. Box 12015, Research Triangle Park, NC 27709.					
	Patient Consent Signat	ure				
	Patient name (print)			Date		
	Patient or representative			Representative		

relationship to patient



Questions about filling out this form?Reach out to the United Therapeutics Cares™ Team.

Mon-Fri, 8:30 am-7 pm ET P: 1-844-864-8437 F: 1-800-380-5294

Patient name:	Date of dirth (MM/DD/YYYY)				
Please have the patient complete and sign (continued)					
Authorization to share health information					
	ase management, and financial assistance for eligible patients. By signing below, lthcare Providers") to share with United Therapeutics and its affiliates, vendors, and ance information ("My Information") for the following purposes:				
① Reviewing my benefits eligibility for a United Therapeutics product.	⑤ Coordinating treatment logistics with My Healthcare Providers.				
② Obtaining insurance coverage information.	(6) De-identifying My Information and combining it with other de-identified				
3 Accessing credit and other data to estimate income, if needed, for financial assistance program eligibility.	data for purposes of research, process and program improvement, and publication.				
(4) Facilitating United Therapeutics Cares support programs.	⑦ Communicating with me via phone, text, email, or mail regarding United Therapeutics Cares, medications, products, or services.				
I understand that once disclosed to United Therapeutics, My Information ma outlined or as required by law. My pharmacy and insurers may receive comp support programs. I acknowledge My Information is subject to the United The Authorization will not impact my treatment, insurance, or benefits but will pre- cancel this Authorization at any time by sending written notice to United There	nerapeutics Privacy Statement (unither.com/privacy). Refusal to sign this event me from participating in United Therapeutics support programs. I may				

emailing opt-out@UnitedTherapeuticsCares.com. Cancellation does not affect prior disclosures. This Authorization expires ten (10) years from the date

below unless revoked earlier or a shorter period is required by law. A copy of this Authorization will be provided upon request.

Patient Consent Signature

Patient name (print)

Sign here: Date

Patient or representat

Representative relationship to patient

Patient or representative signature



Get ready for our call.

We'll call to confirm details of your enrollment soon. Scan to save our information to your contacts.

